The leucocyte adherence inhibition test provides a rapid, reliable, and specific technique for the immunodiagnosis of primary hepatocellular carcinoma (malignant hepatoma). The patient's blood leucocytes are tested in vitro for cell-mediated immunity against tumour-associated antigens and the serum is tested for blocking factor which interferes with the immunological reaction. Specific reactivity of both leucocytes and serum was consistently detected in patients with malignant hepatoma, and negative reactions were obtained in other liver diseases including secondary tumours of the liver. The test has provided positive evidence for the presence of hepatoma when more conventional methods gave doubtful or negative results. A positive result preceded the clinical appearance of tumour by up to three years in two patients.
Possible immunological aids to the diagnosis of primary liver cancer include detection of a-fetoprotein in the serum, demonstration of a specific tissue carcinofetal ferritin (Alpert et al., 1973) , and examination of leucocytes for cell-mediated immunity against tumour-associated antigens. All of these have practical limitations as performed at present. x-Fetoprotein was found in less than 30% of the sera from patients of Caucasian origin with hepatoma, the proportion being greater in Africans (Stillman and Zamcheck, 1970) . Tests for lymphocyte cytotoxicity Jagarlamoody et al., 1971) , lymphocyte transformation (Vanky et al., 1971) , and inhibition of leucocyte migration (Andersen et al., 1969; Segall et al., 1972) are applicable to the detection of specific antitumour cellmediated immunity in a variety of cancers and are potentially applicable to hepatoma; these, however, are complex techniques.
Many and perhaps all human cancers induce the appearance of cytotoxic host lymphocytes capable of killing cultivated tumour cells. This activity is accompanied by circulating blocking factors which interfere with cell-mediated immunity in vitro Jagarlamoody et al., 1971; Vanky et al., 1971) and are probably essential for tumour progression in vivo (Hellstrom et al., 1971 a, b; Hellstrom and Hellstrom, 1973) . Previously described methods for the detection of these cellular and humoral entities require elaborate, time-consuming procedures.
The leucocyte adherence inhibition technique, first described for the study of experimental tumours in mice (Halliday and Miller, 1972; b), has recently been applied to the detection of specific cell-mediated immunity in human cancer Maluish and Halliday, 1974 Patients, Materials, and Methods The patients studied included 7 with primary hepatic tumours (6 with hepatocellular carcinoma, 1 with hepatoblastoma); 3 with secondary hepatic tumours (1 case each of malignant melanoma, adenocarcinoma of the lung, and squamous cell carcinoma of the cervix uteri); 43 with other diseases of the liver, of whom 33 were cirrhotic (9 alcoholics, 8 with chronic active hepatitis, and 16 with haemochromatosis); and 4 with neoplasms not involving the liver (melanoma and adenocarcinomas of the breast, colon, and stomach).
The technique has already been described (Halliday and Miller, 1972; Halliday et al., 1974 a, b; Maluish and Halliday, 1974 (Peterson et al., 1973) . Liver biopsies were performed by the Menghini technique, and the criteria used for the diagnosis of chronic active hepatitis and idiopathic haemochromatosis were those of Cooksley et al. (1972) and Powell (1970) respectively.
Results
Clinical and laboratory data on the patients with primary liver BRITISH MEDICAL JOURNAL 18 MAY 1974 tumours (cases 1-7) and on two with secondary liver tumours (cases 8 and 9) are set out in The hepatoma extract but not the normal control extract inhibited adherence of leucocytes from a patient with hepatoma. These are representative results which were repeated many times. The cell-mediated immunity shown by this test was examined further for specificity by testing the reaction of leucocytes from patients with hepatoma against extracts of other tumours and normal tissues. The results (table III) showed that only hepatoma tissue yielded an antigenically active extract though the other tumour extracts were specifically active with leucocytes from appropriate patients Maluish and Halliday, 1974) . A further distinctive feature of hepatoma was shown when patients' sera were included in the reaction mixtures (table IV) . These sera were observed to block leucocyte adherence inhibition, not only when a patient's own serum was used with his cells but also when the serum and cells originated from different patients with hepatoma. Serum blocking was thus related to tumour type, as was cellular reactivity. Sera from patients with other types of tumours, though blocking with the corresponding antigen, were unreactive in the hepatoma system (table IV) . Conversely serum from patients with hepatoma did not block the interaction of leucocytes and antigens derived from other types of tumours. All of six patients with hepatoma were shown consistently to have specific blocking factor in their serum, some being tested on several occasions over a period of two months (table V) . Four of these had specific leucocyte activity consistently on repeated testing; leucocytes from the other two were unavailable. These patients showed blocking factor in their serum on repeated testing. Leucocytes were available from only one of these patients with blocking serum, and they were found to be specifically active. All cases of cirrhosis, chronic active hepatitis, and secondary hepatic tumours were negative for serum blocking; the single patient with hepatoblastoma had no hepatoma-related activity in either leucocytes or serum. (Powell and Kerr, 1970 (Halliday and Miller, 1972 The nature of the blocking factor in human hepatoma serum has not been studied in detail but there is much information on experimental tumours of rats. Blocking activity related to such tumours could be produced by mixing purified hepatoma antigen with specific antitumour antibody (Baldwin et al., 1972) , thus supporting an earlier suggestion (Sjogren et al., , 1972 that blocking factors in certain other tumour systems are antigenantibody complexes. The proposal that blocking activity may be caused by tumour antigen alone (Currie and Basham, 1972) is not compatible with our findings, since antigen causes inhibition of adherence in these tests, whereas blocking factor has the opposite effect. It is not known whether the cells, antigens, and host responses detected by leucocyte adherence inhibition are exactly the same as those studied by lymphocyte cytotoxicity; superficially they seem to be very similar in terms of specificity and association with tumour growth. It seems unlikely that the hepatoma-associated antigen detected by the test is a-fetoprotein. This antigen was found in only three of the seven patients with primary liver tumours. The active antigen, though found in hepatoma extract, could not be detected (table III) in an extract of fetal liver which presumably contained a-fetoprotein.
Of particular interest was the relation of leucocyte adherence inhibition reactivity to early tumour development. As mentioned above, in cases 5 and 6 a positive test result preceded other clinical and laboratory evidence of hepatoma (table V) , and serum from cases 1 and 4 (table VI) was blocking two and three years respectively before the clinical appearance of their tumours. In a further four patients with primary idiopathic haemochromatosis, which is known to predispose to malignant hepatoma, blocking factor has been detected in the serum (with reactive leucocytes also in one case) but as yet there is no other clinical or laboratory evidence of malignancy. It is suggested that cellmediated immunity and serum blocking may be the earliest detectable manifestation of malignant hepatoma in these patients.
Note added in Proof.-The patient (Case 6) whose diagnosis was unconfirmed has recently died; necropsy examination showed malignant hepatoma.
